This agreement brings together the complementary research and development expertise of both institutions to advance innovative intellectual property from MD Anderson to improve the delivery of radiation therapy for patients with cancer

Getty Images


August 24, 2022 — The University of Texas MD Anderson Cancer Center and Empyrean Medical Systems, Inc. today announced an exclusive license and joint development agreement to advance novel technologies and products in the fields of radiation oncology and cancer therapeutics. 

This agreement brings together the complementary research and development expertise of both institutions to advance innovative intellectual property from MD Anderson to improve the delivery of radiation therapy for patients with cancer. 

“We are proud to collaborate with MD Anderson as we work toward bringing these novel technologies to light,” said Kal Fishman, founder, president, and chief executive officer of Empyrean Medical Systems. “Our goal is to develop multiple state-of-the-art products to deliver optimal radiation therapy for our clinicians and make a real difference for patients and their families.” 

Under this agreement, Empyrean obtains an exclusive license to develop and commercialize a new approach for delivering radiation therapy originally discovered by MD Anderson researchers. The Magnetically Optimized Very High Energy Electron Therapy (MOVHEET) method has the potential to significantly improve the precision of radiation delivered by machinery with a similar footprint to conventional options. 

“The combined expertise of MD Anderson and Empyrean allows us the opportunity to take advantage of dosimetric characteristics of very high energy electron beams for the treatment of malignant tumors,” said Mohammad Salehpour, Ph.D., professor of Radiation Physics at MD Anderson. “The MOVHEET system is designed from the ground up to deliver both conventional and FLASH dose rate radiotherapy with enhanced precision to increase its efficacy.” 

In addition to MOVHEET, Empyrean and MD Anderson intend to collaboratively develop additional technologies based on Empyrean’s intellectual property, all with the goal of optimizing care for patients with cancer. MD Anderson will receive an equity interest in Empyrean and is eligible to receive certain royalties and other financial considerations. 

For more information: https://www.mdanderson.org/ 


Related Content

News | Radiopharmaceuticals and Tracers

December 6, 2023 — Philochem AG, a wholly owned subsidiary of Philogen S.p.A., and Blue Earth Diagnostics, a Bracco ...

Time December 06, 2023
arrow
News | Pediatric Imaging

December 1, 2023 — The Radiation Oncology Program at Children’s Hospital Los Angeles is one of only a few in the country ...

Time December 01, 2023
arrow
News | Artificial Intelligence

November 28, 2023 — iCAD, Inc., a global medical technology leader in innovative cancer-detection solutions, and ...

Time November 28, 2023
arrow
News | Treatment Planning

November 26, 2023 — TeleDaaS, PLLC, a leading dosimetry-as-a-service provider, made its official debut today at the ...

Time November 26, 2023
arrow
News | Breast Imaging

November 21, 2023 —iCAD, Inc., a global medical technology leader in innovative cancer-detection solutions, and CancerIQ ...

Time November 21, 2023
arrow
News | Breast Imaging

November 20, 2023 — The American Society for Radiation Oncology (ASTRO) issued a clinical guideline on partial breast ...

Time November 20, 2023
arrow
News | Artificial Intelligence

November 15, 2023 — The 2023 Radiological Society of North America (RSNA) Alexander R. Margulis Award for Scientific ...

Time November 15, 2023
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

As another month comes to a close, ITN takes a look at the Top 10 most-read pieces of content from www.itnonline.com ...

Time November 06, 2023
arrow
News | ASTRO

November 3, 2023 —The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time November 03, 2023
arrow
Feature | Radiation Oncology | By Melinda Taschetta-Millane

Imaging advancements, including 3D Doppler imaging to detect cancers in numerous organs, are used to accurately guide ...

Time November 03, 2023
arrow
Subscribe Now